Opthea (ASX:OPT) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Opthea Dividend Payout Ratio?

Opthea's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Opthea's Dividend Payout Ratio or its related term are showing as below:

ASX:OPT's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-29), the Dividend Yield % of Opthea is 0.00%.

Opthea's Dividends per Share for the months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Opthea Dividend Payout Ratio Historical Data

The historical data trend for Opthea's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Dividend Payout Ratio Chart

Opthea Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Dividend Payout Ratio

Get a 7-Day Free Trial

Opthea Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Opthea's Dividend Payout Ratio

For the Biotechnology subindustry, Opthea's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Opthea's Dividend Payout Ratio falls into.

Opthea Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Opthea's Dividend Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Jun. 2023 )	/	EPS without NRI (A: Jun. 2023 )
	=	0	/	-0.451
	=	N/A

Opthea's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.244
	=	N/A

Opthea (ASX:OPT) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Opthea Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Opthea's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea (ASX:OPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.